The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a ...
Chronic obstructive pulmonary disease (COPD) is a group of respiratory conditions that include emphysema and chronic bronchitis. It can cause symptoms such as: shortness of breath frequent respiratory ...
In general, having a few drinks in moderation is OK. “One or two drinks a day has not been shown to impact COPD,” says Neil Schachter, MD, a COPD specialist at Mount Sinai Health System. The most ...
Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...
Worsening chronic obstructive pulmonary disease (COPD) symptoms are often underreported by patients who cannot recognize these changes as sign of decline, but they can be objectively measured through ...
While COPD (chronic obstructive pulmonary disease) symptoms may start out as mild to moderate — with episodes of difficulty breathing that come and go — over time, COPD tends to get worse, and many ...
New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely on ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 2026 GOLD report newly highlights disease activity ...
Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...
Though more cases are likely undiagnosed, over 15 million people in the United States have chronic obstructive pulmonary disease (COPD), and 37 million are estimated to have chronic kidney disease ...
Here are the top 5 most-read pulmonary fibrosis articles of 2025.